PCSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-01), Processa Pharmaceuticals's share price is $2.19. Processa Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.88. Hence, Processa Pharmaceuticals's Price to Tangible Book Ratio of today is 0.56.
The historical rank and industry rank for Processa Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Processa Pharmaceuticals's highest Price to Tangible Book Ratio was 416.22. The lowest was 0.54. And the median was 4.42.
A closely related ratio is called PB Ratio. As of today, Processa Pharmaceuticals's share price is $2.19. Processa Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.88. Hence, Processa Pharmaceuticals's P/B Ratio of today is 0.56.
The historical data trend for Processa Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | - | 6.64 | 4.42 | 2.36 | 1.73 |
Processa Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 2.36 | 1.21 | 1.33 | 0.86 | 1.73 |
For the Biotechnology subindustry, Processa Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's Price-to-Tangible-Book falls into.
Processa Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Dec. 2023 ) |
= | 2.19 | / | 3.879 | |
= | 0.56 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Processa Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Wendy Guy | officer: Chief Administrative Officer | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
James H Stanker | officer: Chief Financial Officer | 9008 SHADYBROOK DRIVE, FREDERICK MD 21701 |
Patrick Lin | officer: Chief Business - Strategy Off | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
George K Ng | officer: Chief Executive Officer | C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121 |
Khoso Baluch | director | 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921 |
James R Neal | director | 2910 SEVENTH STREET, BERKELEY CA 94710 |
Virgil Thompson | director | 319 SOUTH NARDO, SOIANA BEACH CA 92075 |
Justin W Yorke | director | C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101 |
Geraldine Pannu | director | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
David Young | director, 10 percent owner, officer: President & CEO | 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045 |
Robert Michael Floyd | officer: Chief Operating Officer | C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
James E Besser | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Khalid Islam | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Sian Bigora | officer: Chief Development Officer | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
From GuruFocus
By PurpleRose PurpleRose • 08-05-2022
By sperokesalga sperokesalga • 05-18-2023
By sperokesalga sperokesalga • 03-30-2023
By Marketwired • 08-10-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 03-23-2023
By PurpleRose PurpleRose • 08-03-2022
By PurpleRose PurpleRose • 08-12-2022
By Marketwired • 09-06-2023
By PurpleRose PurpleRose • 08-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.